Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arvinas stock | 25.55

Own Arvinas stock in just a few minutes.

Posted

Fact checked

Arvinas, Inc is a biotechnology business based in the US. Arvinas shares (ARVN) are listed on the NASDAQ and all prices are listed in US Dollars. Arvinas employs 133 staff and has a trailing 12-month revenue of around USD$46.9 million.

How to buy shares in Arvinas

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Arvinas. Find the stock by name or ticker symbol: ARVN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arvinas reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$25.55, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arvinas, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Arvinas. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Arvinas's share price?

Since the stock market crash in March caused by coronavirus, Arvinas's share price has had significant negative movement.

Its last market close was USD$25.55, which is 49.38% down on its pre-crash value of USD$50.47 and 27.01% down on the lowest point reached during the March crash when the shares fell as low as USD$32.45.

If you had bought USD$1,000 worth of Arvinas shares at the start of February 2020, those shares would have been worth USD$703.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$511.51.

Arvinas share price

Use our graph to track the performance of ARVN stocks over time.

Arvinas shares at a glance

Information last updated 2020-10-19.
Latest market close USD$25.55
52-week range USD$17 - USD$61.57
50-day moving average USD$25.1338
200-day moving average USD$34.7341
Wall St. target price USD$60.8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-7.159

Buy Arvinas shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arvinas stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arvinas price performance over time

Historical closes compared with the close of $25.55 from 2020-11-16

1 week (2020-11-18) 10.56%
1 month (2020-10-26) 21.32%
3 months (2020-08-25) 0.47%
6 months (2020-05-22) -41.98%
1 year (2019-11-25) -25.96%
2 years (2018-11-23) 44.92%
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Arvinas financials

Revenue TTM USD$46.9 million
Gross profit TTM USD$43 million
Return on assets TTM -19.32%
Return on equity TTM -54.53%
Profit margin -182.59%
Book value $5.094
Market capitalisation USD$937.4 million

TTM: trailing 12 months

Shorting Arvinas shares

There are currently 5.7 million Arvinas shares held short by investors – that's known as Arvinas's "short interest". This figure is 4.1% up from 5.4 million last month.

There are a few different ways that this level of interest in shorting Arvinas shares can be evaluated.

Arvinas's "short interest ratio" (SIR)

Arvinas's "short interest ratio" (SIR) is the quantity of Arvinas shares currently shorted divided by the average quantity of Arvinas shares traded daily (recently around 479477.09213863). Arvinas's SIR currently stands at 11.83. In other words for every 100,000 Arvinas shares traded daily on the market, roughly 11830 shares are currently held short.

However Arvinas's short interest can also be evaluated against the total number of Arvinas shares, or, against the total number of tradable Arvinas shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arvinas's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Arvinas shares in existence, roughly 140 shares are currently held short) or 0.1824% of the tradable shares (for every 100,000 tradable Arvinas shares, roughly 182 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arvinas.

Find out more about how you can short Arvinas stock.

Arvinas share dividends

We're not expecting Arvinas to pay a dividend over the next 12 months.

Arvinas share price volatility

Over the last 12 months, Arvinas's shares have ranged in value from as little as $17 up to $61.57. A popular way to gauge a stock's volatility is its "beta".

ARVN.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arvinas's is 1.4863. This would suggest that Arvinas's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Arvinas overview

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site